PureTech Health plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PureTech Health plc
The firm’s lead candidate has shown strong tolerability in an early-stage trial for idiopathic pulmonary fibrosis, sparking hopes for registration-enabling studies and a streamlined development plan.
Vedanta thinks its live biotherapeutic sourced from clonal cell banking could offer strong prevention against C. difficile infections after antibiotics have cleared an initial infection.
PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
- Medical Devices
- Site Specific
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Vedanta Biosciences, Inc.
- Alivio Therapeutics, Inc.
- resTORbio, Inc.
- Tal Medical
- Vor Biopharma